Michelson Diagnostics releases preliminary specification for
handheld OCT probe
16 January 2009
UK company Michelson Diagnostics has issued a preliminary
specification for its clinical optical coherence tomography (OCT) probe
and processing system, which the company says is planned for launch in
late spring this year. The new OCT system has been given the name
Two variants of the new Vivosight probe are specified, one is a
version with X-Y scanning, to enable 3D mapping of flat tissue such as
skin, and the other is a version equipped with a rigid endoscope,
suitable for internal applications. The unique multi-beam design
provides double the image resolution (ie better than 10 μm) available
from conventional single-beam designs, resulting in crisper, clearer OCT
images, showing more clinical detail.
“We will be applying for a CE-mark for the product, which will enable
sales for clinical use in Europe, in the spring 2009 time-frame.” said
Jon Holmes, Chief Executive, “This will be followed by a 510(k) for the
equivalent in the US market.”
Michelson Diagnostics is applying multi-beam OCT to the diagnosis,
monitoring and treatment of cancer, particularly dermal and oral cancer.
The company says it is working closely with leading clinicians,
who believe that multi-beam OCT, by providing a new, detailed window
into the body, will accelerate the care of cancer, enabling faster, more
accurate treatment that will save lives and produce substantial cost
savings to the medical services.
Michelson Diagnostics will be exhibiting a prototype version of the
instrument on stand 8731 at BIOS09, San Jose, USA 24-25 January 2009.
Bookmark this page